Cerity Partners LLC Has $534,000 Stock Holdings in Grifols, S.A. (NASDAQ:GRFS)

Cerity Partners LLC lessened its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 5.8% during the 4th quarter, HoldingsChannel reports. The firm owned 46,232 shares of the biotechnology company’s stock after selling 2,831 shares during the quarter. Cerity Partners LLC’s holdings in Grifols were worth $534,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GRFS. China Universal Asset Management Co. Ltd. grew its stake in shares of Grifols by 106.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,132 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 1,618 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of Grifols in the third quarter worth $136,000. Syon Capital LLC acquired a new stake in shares of Grifols in the third quarter worth $250,000. Raymond James & Associates acquired a new stake in shares of Grifols in the third quarter worth $254,000. Finally, NBC Securities Inc. acquired a new stake in shares of Grifols in the third quarter worth $259,000.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft downgraded shares of Grifols from a “hold” rating to a “sell” rating in a research note on Tuesday, March 12th.

Grifols Stock Down 1.4 %

Shares of GRFS stock opened at $6.39 on Thursday. Grifols, S.A. has a one year low of $5.30 and a one year high of $12.15. The stock has a fifty day moving average price of $7.05 and a 200 day moving average price of $8.36. The company has a quick ratio of 1.32, a current ratio of 2.83 and a debt-to-equity ratio of 1.24.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.